Onchilles Pharma to Present New Preclinical Data for N17350 at AACR 2025
- Press Release
- Mar 25
- 2 min read
March 25, 2025
N17350 is a next-generation cytotoxic agent designed to selectively kill cancer cells independent of anatomical locations, tumor genetics, and tumor immune status, and stimulate the immune system
SAN DIEGO, March 25, 2024 – Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway – a novel cancer-selective killing mechanism enabling potent cancer killing with immune preservation – announced today the presentation of new preclinical data for N17350 at the American Association for Cancer Research® Annual Meeting 2025 (“AACR”), taking place April 25-30, at the McCormick Place Convention Center in Chicago.
Presentation Details:
Title: N17350 outperforms cytotoxic agents in killing tumors of treatment-naïve and chemotherapy-treated ovarian carcinoma patients
Date: Sunday, April 27, 2025
Time: 2PM to 5PM CDT
Location: Poster Section 35
Poster Board Number: 17
Abstract Number: 861
About Onchilles Therapeutic Programs Targeting the ELANE Pathway
At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that targets an essential vulnerability shared by all cancer cells: elevated histone H1 levels. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 (NEU-001) and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity. By targeting the ELANE pathway, these candidates offer a unique approach to treating cancer regardless of their genetic makeup, anatomical origin, or immune status, positioning them as potential game-changers in cancer therapy.
Looking Ahead: Clinical Validation in 2025
Onchilles Pharma plans to initiate a Phase 1 trial of its lead candidate, N17350, in 2025 to validate the ELANE pathway in humans. This trial will further explore the safety and efficacy of this innovative mechanism, representing a significant step toward realizing the potential of ELANE-based therapies.
About Onchilles Pharma
Onchilles Pharma is a global drug discovery and development company pioneering first-in-class cytotoxic therapies designed to selectively kill cancer cells while preserving and activating immune function. By harnessing the ELANE pathway, these next-generation therapeutics are designed to deliver potent and selective tumor cell destruction, overcoming the limitations of traditional chemotherapy and immunotherapy.
The company’s pipeline includes biologic drug candidates aimed at treating various cancers, such as head & neck, skin, breast, and lung cancers, with plans to begin first-in-human trials in 2025. For more information, visit www.onchillespharma.com.
Contacts
Company: Peter Haberz, Ph.D., Vice President, Corporate Development, info@onchillespharma.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com